Page 14 - Double Blind Study News Today

Placebo-controlled trials are insufficient for decisions that affect medication availability in EU member states.

Famed microbiome researcher Dr Martin J. Blaser shares what he sees as the most promising applications, and the rigorous clinical trials needed to realize them.

Findings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages.

Experts urge rigorous research due to safety concerns and uncertainties and prefer naloxone as the preferred first-line agent.

A significant number of patients with moderate to severe atopic dermatitis (AD) failed to achieve adequate disease control with systemic therapies over 12 months, indicating a substantial degree of "therapeutic inertia."

An intracameral implant that releases travoprost into the eye over an extended period to lower intraocular pressure in glaucoma and ocular hypertension will be available commercially in early 2024.

An early trial suggests a combination of psilocybin and psychotherapy may be safe and effective for treatment-resistant depression associated with bipolar II disorder and deserves further study.

Patients with transthyretin amyloid cardiomyopathy taking tafamidis have less worsening of cardiac function than those on placebo, post hoc analysis of randomized results suggests.

Migraine is often thought of as a female disorder, but multiple factors make it difficult to determine its true prevalence in women and men.

A recent Swiss study, despite having a better methodology than previous research, can do little more than fuel hypotheses.